持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2013/11/15 | 日証協 | 51,160株 | +0.8% | 47,305株 | +122.14% | 45,599株 | -4.59% | 5,804株 | -12.05% |
2013/11/08 | 日証協 | 50,755株 | -0.32% | 21,295株 | -54.01% | 47,794株 | +10.5% | 6,599株 | +153.81% |
2013/11/01 | 日証協 | 50,917株 | +3.79% | 46,300株 | +39.22% | 43,251株 | +1.65% | 2,600株 | -29.27% |
2013/10/25 | 日証協 | 49,060株 | -24.59% | 33,257株 | +22.72% | 42,551株 | -7.45% | 3,676株 | -29.03% |
2013/10/18 | 日証協 | 65,060株 | -18.14% | 27,100株 | -72.44% | 45,975株 | +4.26% | 5,180株 | -70.57% |
2013/10/11 | 日証協 | 79,480株 | -36.92% | 98,329株 | +125.38% | 44,095株 | +2.51% | 17,600株 | -71.02% |
2013/10/04 | 日証協 | 125,993株 | +39.43% | 43,629株 | -51.66% | 43,017株 | -33.25% | 60,735株 | +67.2% |
2013/09/27 | 日証協 | 90,360株 | -35.99% | 90,255株 | +28.94% | 64,445株 | -81.91% | 36,325株 | -80.62% |
2013/09/20 | 日証協 | 141,160株 | -72.77% | 70,000株 | -7.89% | 356,236株 | -48.16% | 187,445株 | -39.83% |
2013/09/13 | 日証協 | 518,380株 | -23.98% | 76,000株 | -70.21% | 687,156株 | -17.58% | 311,520株 | -22.89% |
2013/09/06 | 日証協 | 681,860株 | -0.44% | 255,120株 | +153.6% | 833,756株 | -3.79% | 404,000株 | -48.61% |
2013/08/30 | 日証協 | 684,860株 | +0.15% | 100,600株 | -7.72% | 866,636株 | -1.27% | 786,120株 | +37.89% |
2013/08/23 | 日証協 | 683,860株 | -4.52% | 109,020株 | +55.74% | 877,756株 | -5.62% | 570,120株 | -8.4% |
2013/08/16 | 日証協 | 716,260株 | -3.71% | 70,000株 | -77.61% | 930,036株 | -2.06% | 622,400株 | -22.1% |
2013/08/09 | 日証協 | 743,860株 | +1.12% | 312,600株 | +445.36% | 949,636株 | +0.44% | 799,000株 | -19.54% |
2013/08/02 | 日証協 | 735,610株 | +1.73% | 57,320株 | -31.34% | 945,486株 | +5.47% | 993,000株 | +197.31% |
2013/07/26 | 日証協 | 723,090株 | -1.43% | 83,480株 | -47.5% | 896,486株 | -4.02% | 334,000株 | -52.08% |
2013/07/19 | 日証協 | 733,610株 | -1.21% | 159,000株 | -78.05% | 934,006株 | +1.74% | 697,000株 | -3% |
2013/07/12 | 日証協 | 742,610株 | +28.57% | 724,300株 | +23.39% | 918,006株 | +84.9% | 718,520株 | +644.73% |
※株式分割は考慮していませんのでご注意ください。
Page Top